PRTN3 and rheumatoid arthritis: This finding is in agreement with the results from a large cohort of RA patients treated with anti-TNF drugs, in whom the presence of RF or ACPA was associated with a reduced response to treatment, although these antibodies only accounted for a small proportion of the variance in the response and the majority was probably explained by genetic factors [48].